Neutralization of tumor necrosis factor-alpha reduces renal fibrosis and hypertension in rats with renal failure

American Journal of Nephrology

Volumn 36, Issue 2, 2012, Pages 151-161

  Therrien, Frdrick J ^a,b   Agharazii, Mohsen ^a,b   Lebel, Marcel ^a,b   Larivire, Richard ^a,b  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Chronic renal failure; Hypertension; Inflammation; Nuclear transcription factor B; Renal fibrosis; Tumor necrosis factor

Indexed keywords

CREATININE; ENDOTHELIN 1; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR TYPE 1 RECEPTOR; RECOMBINANT CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOSOL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG HALF LIFE; FOCAL GLOMERULOSCLEROSIS; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY MASS; KIDNEY TUBULE ATROPHY; MALE; MEAN ARTERIAL PRESSURE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CHEMOKINE CCL2; DISEASE PROGRESSION; ENDOTHELIN-1; FIBROSIS; HEART RATE; HUMANS; HYPERTENSION, RENAL; INTERCELLULAR ADHESION MOLECULE-1; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RENAL INSUFFICIENCY, CHRONIC; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84863876040     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000340033     Document Type: Article

References (48)

1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16-S23.
2. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005;67:1216-1233. (Pubitemid 40463099)
3. Navarro JF, Mora-Fernandez C: The role of TNF-alpha in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006;17:441-450. (Pubitemid 44803222)
4. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H: Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 2007;30:541-548. (Pubitemid 47083124)
5. Guijarro C, Egido J: Transcription factorkappa b (NF-kappa b) and renal disease. Kidney Int 2001;59:415-424. (Pubitemid 32157906)
6. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM: TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2008;294:R76-R83.
7. Meldrum KK, Metcalfe P, Leslie JA, Misseri R, Hile KL, Meldrum DR: TNF-alpha neutralization decreases nuclear factor-kappaB activation and apoptosis during renal obstruction. J Surg Res 2006;131:182-188.
8. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNFalpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005;67:1812-1820. (Pubitemid 40577716)
9. Sean Eardley K, Cockwell P: Macrophages and progressive tubulointerstitial disease. Kidney Int 2005;68:437-455. (Pubitemid 43323099)
10. Sumagin R, Lomakina E, Sarelius IH: Leukocyteendothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol Heart Circ Physiol 2008;295:H969-H977.
11. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, Muller DN: Vascular endothelial cell-specific NFkappaB suppression attenuates hypertensioninduced renal damage. Circ Res 2007;101:268-276. (Pubitemid 47344076)
12. Bani-Hani AH, Campbell MT, Meldrum DR, Meldrum KK: Cytokines in epithelial-mesenchymal transition: a new insight into obstructive nephropathy. J Urol 2008;180:461-468.
13. Bates RC, Mercurio AM: Tumor necrosis factoralpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 2003;14:1790-1800. (Pubitemid 36583533)
14. Meldrum KK, Misseri R, Metcalfe P, Dinarello CA, Hile KL, Meldrum DR: TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. Am J Physiol Regul Integr Comp Physiol 2007;292:R1456-R1464. (Pubitemid 46557805)
15. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S: Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999;277:F766-F772.
16. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Larivière R: Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 2005;23:1895-1903. (Pubitemid 41830430)
17. Corder R, Carrier M, Khan N, Klemm P, Vane JR: Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol 1995;26 Suppl 3:S56-S58.
18. Marsden PA, Brenner BM: Transcriptional regulation of the endothelin-1 gene by TNFa. Am J Physiol 1992;262:C854-C861.
19. Stenvinkel P: Endothelial dysfunction and inflammation - is there a link? Nephrol Dial Transplant 2001;16:1968-1971. (Pubitemid 32970552)
20. Yoshizumi M, Perreila MA, Burnett JCJ, Lee ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73:205-209. (Pubitemid 23173071)
21. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, Zhang C: Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009;116:219-230.
22. Larivière R, Lebel M: Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003;81:607-621. (Pubitemid 36836395)
23. Dumont Y, D'Amours M, Lebel M, Larivière R: Blood pressure-independent effects of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J Hypertens 2001;19:1479-1487. (Pubitemid 32730466)
24. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001;60:1077-1082. (Pubitemid 34205807)
25. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
26. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D, Remuzzi G: Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997;52:171-181. (Pubitemid 27321828)
27. Vaziri ND, Ni Z, Wang X, Oveisi F, Zhou X: Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 1998;274:F642-F649.
28. Larivière R, D'Amours M, Lebel M, Kingma I, Grose JH, Caron L: Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Pressure Res 1997;20:372-380. (Pubitemid 28021638)
29. Edwards CK 3rd: Pegylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999;58(suppl 1):I73-I81.
30. Larivière R, Lebel M, Kingma I, Grose JH, Boucher D: Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens 1998;11:989-997. (Pubitemid 28378414)
31. Bendele AM, McComb J, Gould T, Frazier J, Chlipala E, Seely J, Kieft G, Edwards CK 3rd: Effects of pegylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol 1999;17:553-560. (Pubitemid 29454825)
32. Misseri R, Meldrum DR, Dinarello CA, Dagher P, Hile KL, Rink RC, Meldrum KK: TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005;288:F406-F411. (Pubitemid 40105400)
33. Dumont Y, D'Amours M, Lebel M, Larivière R: Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol Dial Transplant 2001;16:746-754. (Pubitemid 32257970)
34. Lebel M, Rodrigue ME, Agharazii M, Lariviere R: Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 2006;19:1286-1292. (Pubitemid 44873189)
35. Liu W, Saint DA: A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem 2002;302:52-59. (Pubitemid 34174608)
36. Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001;159:1465-1475. (Pubitemid 32947976)
37. Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, Nikolic-Paterson DJ, Atkins RC, Lan HY: Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998;54:864-876. (Pubitemid 28397404)
38. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Transforming growth factor-beta regulates tubular epithelialmyofibroblast transdifferentiation in vitro. Kidney Int 1999;56:1455-1467. (Pubitemid 29451252)
39. Gomez-Garre D, Ruiz Ortega M, Ortego M, Largo R, Lopez Armada MJ, Plaza JJ, Gonzalez E, Egido J: Effects and interactions of endothelin-1 and angiotensin ii on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996;27:885-892. (Pubitemid 26113835)
40. Rancourt ME, Rodrigue ME, Agharazii M, Lariviere R, Lebel M: Role of oxidative stress in erythropoietin-induced hypertension in uremic rats. Am J Hypertens 2010;23:314-320.
41. Vila E, Salaices M: Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005;288:H1016-H1021. (Pubitemid 40270001)
42. Patel JN, Jager A, Schalkwijk C, Corder R, Douthwaite JA, Yudkin JS, Coppack SW, Stehouwer CD: Effects of tumour necrosis factoralpha in the human forearm: blood flow and endothelin-1 release. Clin Sci 2002;103:409-415. (Pubitemid 35193246)
43. Nakamura M, Yoshida H, Arakawa N, Saitoh S, Satoh M, Hiramori K: Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J Cardiovasc Pharmacol 2000;36:487-492.
44. Ohkita M, Takaoka M, Shiota Y, Nojiri R, Sugii M, Matsumura Y: A nuclear factor-kappab inhibitor bay 11-7082 suppresses endothelin-1 production in cultured vascular endothelial cells. Jpn J Pharmacol 2002;89:81-84. (Pubitemid 34618612)
45. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP: Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005;46:82-86. (Pubitemid 40946495)
46. Waldow T, Witt W, Weber E, Matschke K: Nitric oxide donor-induced persistent inhibition of cell adhesion protein expression and nfkappab activation in endothelial cells. Nitric Oxide 2006;15:103-113. (Pubitemid 44175881)
47. Shahid M, Francis J, Majid DS: Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol 2008;295:F1836-1844.
48. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD: Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and rantes. J Am Soc Nephrol 2004;15:2868-2881. (Pubitemid 41103396)